We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

A Novel Liquid Biopsy Technique for Brain Tumor Diagnosis

By LabMedica International staff writers
Posted on 27 Oct 2020
Print article
Image: Digital droplet PCR (ddPCR): schematic showing oil droplets containing fluorescent PCR target molecules (Photo courtesy of Wikimedia Commons)
Image: Digital droplet PCR (ddPCR): schematic showing oil droplets containing fluorescent PCR target molecules (Photo courtesy of Wikimedia Commons)
A minimally invasive liquid biopsy technique enables diagnosis of glioma, the most common type of brain tumor, by PCR analysis of an easily obtained blood plasma sample.

Detection of TERT (Telomerase reverse transcriptase) promoter mutations (C228T, C250T) in circulating cell free DNA (cfDNA) has been successful for some systemic cancers but has not been demonstrated in gliomas, despite the high prevalence of these mutations in glioma tissue (they are in more than 60% of all gliomas and in 80% of all high-grade gliomas, the most aggressive and life-threatening type). The liquid biopsy approach for brain tumors is complicated, as brain tumor DNA is shed into the bloodstream at much lower levels than that of any other type of tumors.

To improve this situation, investigators at Massachusetts General Hospital (Boston, USA) developed a novel digital droplet PCR assay that incorporated features to improve sensitivity and allowed for the simultaneous detection and longitudinal monitoring of two TERT promoter mutations (C228T and C250T) in cfDNA from the plasma of glioma patients.

Droplet digital PCR (ddPCR) is a method of dPCR in which a 20 microliter sample reaction including assay primers and either Taqman probes or an intercalating dye, is divided into about 20,000 nanoliter-sized oil droplets through a water-oil emulsion technique, thermocycled to endpoint in a 96-well PCR plate, and fluorescence amplitude read for all droplets in each sample well in a droplet flow cytometer.

Results revealed that in baseline performance in tumor tissue, the assay had perfect concordance with an independently performed clinical pathology laboratory assessment of TERT promoter mutations in the same tumor samples. Extending to matched plasma samples, the investigators detected TERT mutations in both discovery and blinded multi-institution validation cohorts with an overall sensitivity of 62.5% and a specificity of 90% compared to the gold standard tumor tissue-based detection of TERT mutations. Upon longitudinal monitoring in five patients, they reported that peripheral TERT mutant allele frequency reflected the clinical course of the disease with levels decreasing after surgical intervention and therapy and increasing with tumor progression.

"Liquid biopsy is particularly challenging in brain tumors because mutant DNA is shed into the bloodstream at much lower level than any other types of tumors," said contributing author Dr. Leonora Balaj, investigator in neurosurgery at Massachusetts General Hospital. "By “supercharging” our ddPCR assay with novel technical improvements, we showed for the first time that the most prevalent mutation in malignant gliomas can be detected in blood, opening a new landscape for detection and monitoring of the tumors. The test is easy to use, quick, and low cost, and could be performed in most laboratories. Importantly, the test can also be used to follow the course of disease."

The glioma liquid biopsy paper was published in the October 13, 2020, online edition of the journal Clinical Cancer Research.

Related Links:
Massachusetts General Hospital

New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Cortisol Rapid Test
Finecare Cortisol Rapid Quantitative Test
New
Flow Cytometer
BF – 710

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more